Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
Identifieur interne : 001764 ( Main/Corpus ); précédent : 001763; suivant : 001765Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
Auteurs : Maximilian F. Konig ; Alfred Hj Kim ; Marc H. Scheetz ; Elizabeth R. Graef ; Jean W. Liew ; Julia Simard ; Pedro M. Machado ; Milena Gianfrancesco ; Jinoos Yazdany ; Daman Langguth ; Philip C. RobinsonSource :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antirheumatic Agents (blood), Antirheumatic Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Case-Control Studies (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Dose-Response Relationship, Drug (MeSH), Extracorporeal Membrane Oxygenation (statistics & numerical data), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Hydroxychloroquine (blood), Hydroxychloroquine (therapeutic use), Lupus Erythematosus, Systemic (drug therapy), Lupus Erythematosus, Systemic (epidemiology), Male (MeSH), Middle Aged (MeSH), Oxygen Inhalation Therapy (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Respiration, Artificial (statistics & numerical data), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH).
- MESH :
- chemical , blood : Antirheumatic Agents, Hydroxychloroquine.
- chemical , therapeutic use : Antirheumatic Agents, Hydroxychloroquine.
- drug therapy : Lupus Erythematosus, Systemic.
- epidemiology : Coronavirus Infections, Lupus Erythematosus, Systemic, Pneumonia, Viral.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Extracorporeal Membrane Oxygenation, Hospitalization, Respiration, Artificial.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Betacoronavirus, COVID-19, Case-Control Studies, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pandemics, SARS-CoV-2, Severity of Illness Index.
DOI: 10.1136/annrheumdis-2020-217690
PubMed: 32381561
Links to Exploration step
pubmed:32381561Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.</title><author><name sortKey="Konig, Maximilian F" sort="Konig, Maximilian F" uniqKey="Konig M" first="Maximilian F" last="Konig">Maximilian F. Konig</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Alfred Hj" sort="Kim, Alfred Hj" uniqKey="Kim A" first="Alfred Hj" last="Kim">Alfred Hj Kim</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheetz, Marc H" sort="Scheetz, Marc H" uniqKey="Scheetz M" first="Marc H" last="Scheetz">Marc H. Scheetz</name><affiliation><nlm:affiliation>Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Graef, Elizabeth R" sort="Graef, Elizabeth R" uniqKey="Graef E" first="Elizabeth R" last="Graef">Elizabeth R. Graef</name><affiliation><nlm:affiliation>Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liew, Jean W" sort="Liew, Jean W" uniqKey="Liew J" first="Jean W" last="Liew">Jean W. Liew</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Simard, Julia" sort="Simard, Julia" uniqKey="Simard J" first="Julia" last="Simard">Julia Simard</name><affiliation><nlm:affiliation>Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><affiliation><nlm:affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Langguth, Daman" sort="Langguth, Daman" uniqKey="Langguth D" first="Daman" last="Langguth">Daman Langguth</name><affiliation><nlm:affiliation>Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation><nlm:affiliation>The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32381561</idno><idno type="pmid">32381561</idno><idno type="doi">10.1136/annrheumdis-2020-217690</idno><idno type="wicri:Area/Main/Corpus">001764</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001764</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.</title><author><name sortKey="Konig, Maximilian F" sort="Konig, Maximilian F" uniqKey="Konig M" first="Maximilian F" last="Konig">Maximilian F. Konig</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Alfred Hj" sort="Kim, Alfred Hj" uniqKey="Kim A" first="Alfred Hj" last="Kim">Alfred Hj Kim</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheetz, Marc H" sort="Scheetz, Marc H" uniqKey="Scheetz M" first="Marc H" last="Scheetz">Marc H. Scheetz</name><affiliation><nlm:affiliation>Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Graef, Elizabeth R" sort="Graef, Elizabeth R" uniqKey="Graef E" first="Elizabeth R" last="Graef">Elizabeth R. Graef</name><affiliation><nlm:affiliation>Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liew, Jean W" sort="Liew, Jean W" uniqKey="Liew J" first="Jean W" last="Liew">Jean W. Liew</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Simard, Julia" sort="Simard, Julia" uniqKey="Simard J" first="Julia" last="Simard">Julia Simard</name><affiliation><nlm:affiliation>Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><affiliation><nlm:affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Langguth, Daman" sort="Langguth, Daman" uniqKey="Langguth D" first="Daman" last="Langguth">Daman Langguth</name><affiliation><nlm:affiliation>Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation><nlm:affiliation>The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antirheumatic Agents (blood)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (physiopathology)</term><term>Coronavirus Infections (therapy)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Extracorporeal Membrane Oxygenation (statistics & numerical data)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (blood)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Lupus Erythematosus, Systemic (epidemiology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (therapy)</term><term>Respiration, Artificial (statistics & numerical data)</term><term>SARS-CoV-2 (MeSH)</term><term>Severity of Illness Index (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lupus Erythematosus, Systemic</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Lupus Erythematosus, Systemic</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Extracorporeal Membrane Oxygenation</term><term>Hospitalization</term><term>Respiration, Artificial</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Betacoronavirus</term><term>COVID-19</term><term>Case-Control Studies</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Oxygen Inhalation Therapy</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32381561</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.</ArticleTitle><Pagination><MedlinePgn>1386-1388</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2020-217690</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konig</LastName><ForeName>Maximilian F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0001-5045-5255</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Alfred Hj</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0003-4074-0516</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheetz</LastName><ForeName>Marc H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graef</LastName><ForeName>Elizabeth R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Jean W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Pedro M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-8411-7972</Identifier><AffiliationInfo><Affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianfrancesco</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdany</LastName><ForeName>Jinoos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langguth</LastName><ForeName>Daman</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-3156-3418</Identifier><AffiliationInfo><Affiliation>The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Global Rheumatology Alliance</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR073752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR048522</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070155</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AR074534</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AR072421</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">epidemiology</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="Y">pharmacokinetics</Keyword></KeywordList><CoiStatement>Competing interests: MFK received personal fees from Bristol-Myers Squibb and Celltrion, unrelated to this manuscript. AHK received personal fees from Exagen Diagnostics, Inc and GlaxoSmithKline, unrelated to this manuscript. PMM received personal fees from Abbvie, Eli Lilly, Novartis and UCB Pharma. JY received personal fees from Astra Zeneca and Eli Lilly, unrelated to this manuscript. PCR reports personal fees from Abbvie, Pfizer, UCB Pharma, Novartis, Eli Lilly and Janssen, and non-financial support from Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32381561</ArticleId><ArticleId IdType="pii">annrheumdis-2020-217690</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-217690</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001764 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001764 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32381561
|texte= Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32381561" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |